Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Prototype CTC Collection Device Tested Successfully in Model

By LabMedica International staff writers
Posted on 08 Apr 2019
A novel, wearable device for continuous isolation of circulating tumor cells (CTCs) from a peripheral vein was tested successfully in a dog model of human cancer.

CTCs are now an established biomarker for prognosis in patients with various carcinomas. More...
However, current CTC isolation technologies rely on small blood volumes from a single venipuncture limiting the number of captured CTCs. This produces statistical variability and inaccurate reflection of tumor cell heterogeneity.

To improve this situation, investigators at the University of Michigan (Ann Arbor, USA) and collaborators at Colorado State University (Fort Collins, USA) designed an in vivo indwelling intravascular CTC isolation device to continuously collect CTCs directly from a peripheral vein. The system would return the remaining blood products after CTC enrichment, permitting interrogation of larger blood volumes than could be obtained by classic phlebotomy over a prolonged period of time.

The investigators produced a prototype wearable device that utilized novel protocols for mixing blood with the clot-inhibiting drug heparin and that employed sterilization methods for killing bacteria without harming the cell-targeting antibodies on the chip. The chip itself incorporated the nanomaterial graphene oxide to create a dense matrix of antibody-tipped molecular chains, which enabled it to trap more than 80% of the cancer cells from the whole blood that flowed across it.

The investigators reported in the April 1, 2019, online edition of the journal Nature Communications that they had validated the system in canine models. Results demonstrated the capability for screening 1–2% of the animal's entire blood supply over a period of two hours. This approach yielded a substantial increase in CTC capture, compared with serial blood draws.

"Nobody wants to have a biopsy. If we could get enough cancer cells from the blood, we could use them to learn about the tumor biology and direct care for the patients. That is the excitement of why we are doing this," said senior author Dr. Daniel F. Hayes, professor of internal medicine at the University of Michigan. "This is the epitome of precision medicine, which is so exciting in the field of oncology right now."

Related Links:
University of Michigan
Colorado State University


New
Gold Member
Immunochromatographic Assay
CRYPTO Cassette
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Laboratory Software
ArtelWare
New
8-Channel Pipette
SAPPHIRE 20–300 µL
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: New research points to protecting blood during radiation therapy (Photo courtesy of 123RF)

Pioneering Model Measures Radiation Exposure in Blood for Precise Cancer Treatments

Scientists have long focused on protecting organs near tumors during radiotherapy, but blood — a vital, circulating tissue — has largely been excluded from dose calculations. Each blood cell passing through... Read more

Immunology

view channel
Image: The test could streamline clinical decision-making by identifying ideal candidates for immunotherapy upfront (Xiao, Y. et al. Cancer Biology & Medicine July 2025, 20250038)

Blood Test Predicts Immunotherapy Efficacy in Triple-Negative Breast Cancer

Triple-negative breast cancer (TNBC) is an aggressive subtype lacking targeted therapies, making immunotherapy a promising yet unpredictable option. Current biomarkers such as PD-L1 expression or tumor... Read more

Microbiology

view channel
Image: New diagnostics could predict a woman’s risk of a common sexually transmitted infection (Photo courtesy of 123RF)

New Markers Could Predict Risk of Severe Chlamydia Infection

Chlamydia trachomatis is a common sexually transmitted infection that can cause pelvic inflammatory disease, infertility, and other reproductive complications when it spreads to the upper genital tract.... Read more

Technology

view channel
Image: The sensor can help diagnose diabetes and prediabetes on-site in a few minutes using just a breath sample (Photo courtesy of Larry Cheng/Penn State)

Graphene-Based Sensor Uses Breath Sample to Identify Diabetes and Prediabetes in Minutes

About 37 million U.S. adults live with diabetes, and one in five is unaware of their condition. Diagnosing diabetes often requires blood draws or lab visits, which are costly and inconvenient.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.